Objective  To explore the clinical efficacy and safety of azithromycin sequential therapy combined with risk management in the treatment of mycoplasmal pneumonia pneumonia (MPP) in children.

Methods  MPP children admitted to the Department of Pediatrics of Quzhou People's Hospital from March 2023 to November 2023 were retrospectively selected, and divided into a study group (azithromycin sequential therapy combined with risk management) and a control group (azithromycin sequential therapy combined with routine care) according to different intervention methods. The clinical efficacy, inflammatory cytokines [interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α)], incidence of MPP-related complications, and incidence of drug-related adverse reactions (DRAR) in the two groups after treatment were observed and compared.

Results  A total of 119 children with MPP were included in the study, with 57 in the study group and 62 in the control group. The clinical efficacy of children with MPP in the study group was significantly higher than that in the control group (P<0.05). There was no significant difference in IL-6, IL-17, and TNF-α between the two groups before treatment (P>0.05); after treatment, both groups showed significant decreases in IL-6, IL-17, and TNF-α compared with before treatment, and these indicators of the study group were lower than thsoe of the control group (P<0.05). The incidence of MPP-related complications in children in the study group was lower than that in the control group (P<0.05), and there was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). In addition, the satisfaction of MPP children’s family members in the study group with nursing care was significantly higher than that in the control group (P<0.05).

Conclusion  The clinical efficacy of azithromycin sequential therapy combined with risk management in the treatment of pediatric MPP is significant, which can regulate the expression of inflammatory cytokines, reduce MPP-related complications, and improve clinical efficacy and family satisfaction with nursing care.

1.Krafft C, Christy C. Mycoplasma pneumonia in children and adolescents[J]. Pediatr Rev, 2020, 41(1): 12-19. DOI: 10.1542/pir.2018-0016.

2.Kumar S. Mycoplasma pneumoniae: a significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections[J]. Indian J Med Res, 2018, 147(1): 23-31. DOI: 10.4103/ijmr.IJMR_1582_16.

3.冯伟静, 陈建, 董泽伍. 痰热清联合甲泼尼龙治疗小儿重症支原体肺炎患者的疗效[J]. 西部医学, 2023, 35(12): 1813-1816. [Feng WJ, Chen J, Dong ZW. Efficacy of tanreqing combined with methylprednisolone in the treatment of severe mycoplasmal pneumonia in children[J]. Medical Journal of West China, 2023, 35(12): 1813-1816.] DOI: 10.3969/j.issn.1672-3511.2023.12.018.

4.刘铸容, 向静瑶, 蒋振兴, 等. 血清唾液酸、C3在支原体肺炎合并气道黏液栓患儿中的临床意义[J]. 西部医学, 2023, 35(9): 1368-1372. [Liu ZR, Xiang  JY, Jiang ZX, et al. Clinical significance of serum sialic acid and C3 in children with mycoplasmal pneumonia complicated with airway mucus plug[J]. Medical Journal of West China, 2023, 35(9): 1368-1372.] DOI: 10.3969/j.issn.1672-3511.2023.09.024.

5.国春柘, 成芳, 薛乔, 等. 小儿支原体肺炎血Th17/Treg细胞失衡与心肌损害发生的相关性[J]. 西部医学, 2023, 35(12): 1822-1825. [Guo CZ, Cheng F, Xue  Q, et al. The correlation between the imbalance of Th17/Treg cells in children with mycoplasmal pneumonia and the occurrence of myocardial damage[J]. Medical Journal of West China, 2023, 35(12): 1822-1825.] DOI: 10.3969/j.issn.1672-3511.2023.12.020.

6.孙小野. 许昌地区不同年龄段小儿肺炎支原体肺炎临床特点分析[J]. 数理医药学杂志, 2022, 35(4): 542-544. [Sun XY. Analysis of clinical characteristics of mycoplasmal pneumonia in children of different ages in Xuchang area[J]. Journal of Mathematical Medicine, 2022, 35(4): 542-544.] DOI: 10.3969/j.issn.1004-4337.2022.04.023.

7.明建军, 杨巧玲, 孙华君, 等. 环丙沙星治疗儿童耐大环内酯类支原体肺炎的回顾性分析[J]. 药物流行病学杂志, 2022, 31(12): 803-807. [Ming JJ, Yang QL, Sun HJ, et al. Retrospective analysis of ciprofloxacin in the treatment of children with macrolide-resistant mycoplasmal pneumonia[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(12): 803-807.] DOI: 10.19960/j.cnki.issn1005-0698.2022.12.004.

8.武华军, 杨秋香, 赵琳, 等. 替加环素治疗1例小儿耐药支原体合并多重耐药鲍曼不动杆菌感染的分析 [J]. 药物流行病学杂志, 2022, 31(10): 679-682. [Wu HJ, Yang QX, Zhao L, et al. Analysis of tigecycline treatment for a child with drug-resistant mycoplasma combined with multi-drug-resistant Acinetobacter baumannii infection[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(10): 679-682.] DOI: 10.19960/j.cnki.issn1005-0698.2022.10.006.

9.Hu X, Zhang X, Wang Y, et al. Cross-sectional study on the drug utilization and evaluation indicator of antibiotics used in pediatric population[J]. BMC Health Serv Res, 2021, 21(1): 1091. DOI: 10.1186/s12913-021-06727-3.

10.刘美红. 风险管理联合细节护理在心血管介入导管室围术期中的应用[J]. 黑龙江医药, 2023, 36(5): 1222-1224. [Liu MH. The application of risk management combined with detailed nursing in the perioperative period of cardiovascular intervention catheter room[J]. Heilongjiang Medicine Journal, 2023, 36(5): 1222-1224.] DOI: 10.14035/j.cnki.hljyy.2023.05.082.

11.刘松梅, 郭金颖. 风险管理护理联合阿奇霉素治疗小儿支原体肺炎效果观察[J]. 齐齐哈尔医学院学报, 2021, 42(16): 1450-1452. [Liu SM, Guo JY. Observation on the effect of risk management nursing combined with azithromycin in the treatment of pediatric mycoplasma pneumonia[J]. Journal of Qiqihar University of Medicine, 2021, 42(16): 1450-1452.] DOI: 10.3969/j.issn.1002-1256.2020.16.019.

12.谷艳娟, 邓童林, 梁钰珊. 阿奇霉素序贯疗法治疗小儿肺炎支原体感染时应用风险管理护理对治疗安全性与临床疗效的影响[J]. 吉林医学, 2020, 41(3): 743-745. [Gu YJ, Deng TL, Liang YS. The impact of risk management nursing on the safety and clinical efficacy of azithromycin sequential therapy in the treatment of Mycoplasma pneumoniae infection in children[J]. Jilin Medical Journal, 2020, 41(3): 743-745.] DOI: 10.3969/j.issn.1004-0412.2020.03.113.

13.宋姚, 侯璐莹, 高文静. 护理风险管理对慢性阻塞性肺疾病急性加重期患者预后的影响[J]. 临床医学研究与实践, 2022, 7(21): 161-163. [Song Y, Hou LY, Gao WJ. The impact of nursing risk management on the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Clinical Research and Practice, 2022, 7(21): 161-163.] DOI: 10.19347/j.cnki.2096-1413. 202221045.

14.王海霞, 马忻凡. 护理风险管理对大剂量甲泼尼龙治疗小儿特发性血小板减少性紫癜的血栓弹力图参数及预后的影响[J]. 血栓与止血学, 2022, 28(1): 152-154. [Wang HX, Ma XF. The impact of nursing risk management on the thromboelastogram parameters and prognosis of high-dose methylprednisolone treatment for pediatric idiopathic thrombocytopenic purpura[J]. Chinese Journal of Thrombosis and Hemostasis, 2022, 28(1): 152-154.] DOI: 10.3969/j.issn.1009-6213.2022.01.070.

15.苏布德格日乐, 刘伟民, 斯琴格日勒, 等. 儿童肺炎支原体肺炎急性期高分辨率CT特征与血清炎症因子、病情严重程度及预后的相关性[J]. 放射学实践, 2023, 38(9): 1173-1177. [Su Bude Ge Ri Le, Liu WM, Si Qin Ge Ri Le, et al. The correlation between high-resolution CT features of acute stage Mycoplasma pneumoniae pneumonia in children and serum inflammatory factors, severity of the condition, and prognosis[J]. Radiologic Practice, 2023, 38(9): 1173-1177.] DOI: 10.13609/j.cnki.1000-0313.2023. 09.016.

16.钟吓玲. 综合护理在儿童肺炎支原体感染治疗中的应用效果[J]. 中国医药指南, 2023, 21(17): 165-167. [Zhong XL. The application effect of comprehensive nursing in the treatment of Mycoplasma pneumoniae infection in children[J]. Guide of China Medicine, 2023, 21(17): 165-167.] DOI: 10.15912/j.cnki.gocm.2023.17.001.

17.张燕红. 家属协同护理对肺炎支原体感染患儿的效果及预后的影响[J]. 中国医药科学, 2023, 13(16): 119-121, 190. [Zhang YH. The effect and prognosis of family collaboration nursing on children infected with Mycoplasma pneumoniae[J]. China Medicine and Pharmacy, 2023, 13(16): 119-121, 190.] DOI: 10.20116/j.issn2095-0616.2023.16.28.

18.Norton AE, Konvinse K, Phillips EJ, et al. Antibiotic allergy in pediatrics[J]. Pediatrics, 2018, 141(5): e20172497. DOI: 10.1542/peds.2017-2497.

19.Smith C, Egunsola O, Choonara I, et al. Use and safety of azithromycin in neonates: a systematic review[J]. BMJ Open, 2015, 5(12): e008194. DOI: 10.1136/bmjopen- 2015-008194.

20.高建龙. 阿奇霉素序贯治疗结合常规疗法在小儿支原体肺炎中的疗效分析[J]. 中国妇幼保健, 2020, 35(4): 660-662. [Gao JL. Analysis of the therapeutic effect of azithromycin sequential therapy combined with conventional therapy in children with mycoplasma pneumonia[J]. Maternal & Child Health Care of China, 2020, 35(4): 660-662.] DOI: 10.19829/j.zgfybj.issn.1001-4411.2020.04.025.

21.李娟, 颜维孝, 马如海. 重症MPP患儿外周血Th1/Th2类细胞因子变化及对近期预后不良的预测分析[J]. 中国免疫学杂志, 2023, 39(10): 2222-2226. [Li J, Yan WX, Ma RH. The changes of Th1/Th2cytokines in peripheral blood of children with severe MPP and their predictive analysis for short-term poor prognosis[J]. Chinese Journal of Immunology, 2023, 39(10): 2222-2226.] DOI: 10.3969/j.issn.1000-484X.2023.10.036.